Pfizer and BioNTech announced their COVID-19 vaccine was 100% effective in adolescents 12 to 15 years old

BioNTech and Pfizer laboratories announced on Wednesday that their coronavirus vaccine was 100% effective in young people aged 12 to 15. and they hoped to start vaccinating them before the start of the next school year.

Phase 3 clinical trials in 2260 adolescents in the United States “have shown 100% efficacy and a robust response in the form of antibodies “the companies said in a statement.

“We plan to send this data to the FDA (the US regulator) as a Proposal for an amendment to our emergency use authorization in the coming weeks and to other regulators around the world, Hope that start vaccinating this age group before the next school year ”, said the CEO of Pfizer, Albert Bourla.

The CEO of German company BioNTech said the results showing high protection for adolescents are “very encouraging considering the trends we have observed in recent weeks con the distribution of the British variant B.1.1.7 ”.

The BioNTech / Pfizer injection is based on new mRNA technology and was the first Covid-19 vaccine approved in the West late last year.

Both United States as the European Union have been approved for use by persons over 16 years of age.

Since, It has been used by millions of adults in over 65 countries.

A real-world study of 1.2 million people in Israel found he had a 94 percent effective.

As the world scrambled to inoculate, BioNTech said on Tuesday it was on its way to manufacturing. 2.5 billion doses of his vaccine this year.

The increase in production was driven by the recent launch of a new production site in the German city of Marburg, which is now one of the largest mRNA vaccine manufacturing plants in the world, he said.

The vaccine is also in progress produce in a Pfizer factory in Belgium and in three locations in the United States.

BioNTech said that improving the efficiency and new cooperation agreements with external partners They had also helped raise its vaccine target, as had the regulatory green light that allows vaccinators to withdraw six doses instead of just five from a single vial of BioNTech / Pfizer.

BioNTech and Pfizer started last week Injection studies in children and the first group of children aged 5 to 11 received the vaccine.

It’s expected that a younger cohort of children aged two to five receive their first dose next week in the study, which will also cover children up to the age of six months.

KEEP READING: